ABSTRACT
Colchicine myopathy typically presents acutely to subacutely with progressive limb weakness. The patients may not be on high doses of colchicine but almost always have acute kidney injury. Dehydration from colchicine-induced diarrhoea is often a precipitating factor. The concomitant neurotoxicity may produce mild sensory complaints. This combination of acute neurological symptoms preceded by diarrhoea prompts the diagnosis of Guillain-Barre syndrome (GBS). The absence of cranial nerve deficits, raised creatine kinase and myotonic discharges on electromyogram may help in differentiating this condition from GBS. We describe a clinical sign, myoedema - a mounding phenomenon of muscle that is elicited by percussion and resolves when the patient recovers. It aids in the bedside diagnosis of acute colchicine myopathy as well as distinguish it from other more common causes of acute flaccid paralysis. We also discuss the possible mechanism of colchicine toxicity and the mounding phenomenon.
Subject(s)
Guillain-Barre Syndrome , Muscular Diseases , Neuromuscular Diseases , Humans , Colchicine/adverse effects , Muscular Diseases/chemically induced , Muscular Diseases/diagnosis , Muscular Diseases/complications , Neuromuscular Diseases/chemically induced , Guillain-Barre Syndrome/diagnosis , Diarrhea/chemically inducedABSTRACT
OBJECTIVE: To identify reports of colchicine-induced neuropathy and myopathy and ascertain risk factors associated with this toxicity at commonly used doses. METHODS: A systematic review of case reports was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA methodology). PubMed and EMBASE were searched through October 2021 for case reports of neuropathy and/or myopathy associated with the use of colchicine at therapeutic doses. RESULTS: A total of 143 cases of neuromyopathy from 99 articles were identified as having a "definite" or "probable" association with colchicine usage, as assessed by the Naranjo algorithm. Most of these cases presented with features of both neuropathy and myopathy (n=72, 51%) but symptoms of myopathy were predominant. The mean total daily dose was 1.25±0.60 mg and 48% had been taking colchicine for more than 12 months before presenting with neuromyopathy. A total of 117 (82%) of all reports had either a significant co-morbidity or possible colchicine drug-drug interaction, while 57 (40%) had both risk factors. A total of 26 cases (18%) had no significant risk factor but only 15 of these reports contained complete descriptions of the patient's co-morbidities and co-medications. Cessation of colchicine generally led to complete resolution of symptoms in 70% of cases within a median of 21 days. There were 3 deaths reported which were due to multi-organ failure despite cessation of colchicine and medical management. Colchicine was restarted at reduced doses in 15 cases and 73% had no symptom recurrence. CONCLUSION: Neuromyopathy is an uncommon but reported adverse effect of colchicine. Cases generally present with proximal myopathy symptoms. Cases of colchicine neuromyopathy are largely reported in patients on commonly used doses. Renal and hepatic dysfunction and medications that inhibit cytochrome P450 3A4 isozyme (CYP3A4) and P-glycoprotein (P-gp) appear to be the most significant risk factors. Fortunately, cessation of colchicine generally leads to complete resolution of symptoms. Recommencement of colchicine at reduced doses appeared to be usually safe.
Subject(s)
Muscular Diseases , Neuromuscular Diseases , Peripheral Nervous System Diseases , Humans , Colchicine/adverse effects , Neuromuscular Diseases/chemically induced , Neuromuscular Diseases/drug therapy , Muscular Diseases/chemically induced , Muscular Diseases/drug therapy , Peripheral Nervous System Diseases/chemically induced , Risk FactorsABSTRACT
Intrapleural injections of cholera toxin B conjugated to saporin (CTB-SAP) selectively eliminates respiratory (e.g., phrenic) motor neurons, and mimics motor neuron death and respiratory deficits observed in rat models of neuromuscular diseases. Additionally, microglial density increases in the phrenic motor nucleus following CTB-SAP. This CTB-SAP rodent model allows us to study the impact of motor neuron death on the output of surviving phrenic motor neurons, and the underlying mechanisms that contribute to enhancing or constraining their output at 7 days (d) or 28d post-CTB-SAP injection. 7d CTB-SAP rats elicit enhanced phrenic long-term facilitation (pLTF) through the Gs-pathway (inflammation-resistant in naïve rats), while pLTF is elicited though the Gq-pathway (inflammation-sensitive in naïve rats) in control and 28d CTB-SAP rats. In 7d and 28d male CTB-SAP rats and controls, we evaluated the effect of cyclooxygenase-1/2 enzymes on pLTF by delivery of the nonsteroidal anti-inflammatory drug, ketoprofen (IP), and we hypothesized that pLTF would be unaffected by ketoprofen in 7d CTB-SAP rats, but pLTF would be enhanced in 28d CTB-SAP rats. In anesthetized, paralyzed and ventilated rats, pLTF was surprisingly attenuated in 7d CTB-SAP rats and enhanced in 28d CTB-SAP rats (both p < 0.05) following ketoprofen delivery. Additionally in CTB-SAP rats: 1) microglia were more amoeboid in the phrenic motor nucleus; and 2) cervical spinal inflammatory-associated factor expression (TNF-α, BDNF, and IL-10) was increased vs. controls in the absence of ketoprofen (p < 0.05). Following ketoprofen delivery, TNF-α and IL-10 expression was decreased back to control levels, while BDNF expression was differentially affected over the course of motor neuron death in CTB-SAP rats. This study furthers our understanding of factors (e.g., cyclooxygenase-1/2-induced inflammation) that contribute to enhancing or constraining pLTF and its implications for breathing following respiratory motor neuron death.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Ketoprofen/pharmacology , Long-Term Potentiation/drug effects , Motor Neurons/drug effects , Phrenic Nerve/drug effects , Animals , Cell Death/drug effects , Cholera Toxin/toxicity , Male , Microglia/metabolism , Motor Neurons/pathology , Neuromuscular Diseases/chemically induced , Neuromuscular Diseases/pathology , Neuromuscular Diseases/physiopathology , Phrenic Nerve/pathology , Rats , Rats, Sprague-Dawley , Saporins/toxicityABSTRACT
AIM: Despite unprecedented results of anti-programmed death protein (ligand) 1 (PD-(L)1) immune checkpoint inhibitor in the oncology's armamentarium, immune-related adverse events (irAEs) represent a therapeutic hurdle. Currently, there is no consensual recommendation on a routinely monitored biomarker to early detect irAE. Biological markers such as serum creatine phosphokinase (CPK) are commonly used to measure muscular tissue injury. The potential of routine serum CPK monitoring to predict cardiac or neuromuscular irAE in patients treated with immunotherapy remains unknown. METHODS: In this retrospective study between January 2016 and December 2018 at Gustave Roussy Cancer Campus, 1151 cancer patients treated with anti-PD-(L)1 immunotherapy were systematically monitored with serum CPK measurements before each immunotherapy cycle. We considered significant CPK increases according to Common Terminology Criteria for Adverse Events v5.0 (CTCAEV5) of grade ≥2 severity. Comparisons were performed in patients with immune-related CPK (ir-CPK) elevations symptomatic versus asymptomatic. RESULTS: Overall, 53 of 1151 (4.6%) patients showed a CPK increase. Elevations of CPK were deemed to be immunotherapy-related in 31 of 1151 (2.7%) patients. Among them, 12 of 31 (38.7%) patients experienced symptomatic cardiac or neuromuscular irAE, whereas the other 19 of 31 (61.3%) patients remained asymptomatic. In patients with symptomatic irAE, the mean ir-CPK level was higher compared with asymptomatic patients (1271 versus 771 UI/L, P value = 0.02). In the asymptomatic group, all patients experienced a spontaneous resolution of the ir-CPK increase, and none required medical intervention. CONCLUSION: Most patients with immune-related CPK increase remained asymptomatic. The CPK serum increase did not alter the clinical management of asymptomatic patients. The results of this study did not support a significant clinical interest for a systematic routine CPK monitoring in patients amenable to anti-PD-(L)1 immunotherapy.
Subject(s)
Cardiotoxicity/diagnosis , Creatine Kinase/blood , Immune Checkpoint Inhibitors/adverse effects , Neoplasms/drug therapy , Neuromuscular Diseases/diagnosis , B7-H1 Antigen/antagonists & inhibitors , Biomarkers/blood , Cardiotoxicity/blood , Cardiotoxicity/immunology , Feasibility Studies , Female , Humans , Male , Memory, Episodic , Middle Aged , Neoplasms/blood , Neuromuscular Diseases/blood , Neuromuscular Diseases/chemically induced , Neuromuscular Diseases/immunology , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Retrospective StudiesABSTRACT
3-Dimensional (3D) printing and bioprinting are the new technologies. In 3D printing, synthetic polymers such as acrylonitrile, butadiene, and styrene, polylactic acid, nylon, and some metals are used as feedstocks. During 3D printing, volatile organic compounds (VOCs) and nanoparticles can be released. In the bioprinting process, natural polymers are most commonly used. All of these materials have direct and indirect toxic effects in exposed people. Therefore, the aim of this study was to provide a comprehensive review of toxicity risks due to occupational exposure to pollutants in the 3D printing and bioprinting industries. The Cochrane review method was used as a guideline for systematic review. Articles were searched in the databases including PubMed, Scopus, Web of Science, and Google Scholar. This systematic review showed that VOCs and ultra-fine particles are often released in fused deposition modeling and selective laser sintering, respectively. Asthma, chronic obstructive pulmonary disease, allergic rhinitis, and DNA damage were observed in occupational exposure to synthetic polymers. Metal nanoparticles can induce adverse health effects on the respiratory and nervous systems. This study emphasized the need to further study the toxicity of 3D printing and bioprinting-induced air pollutants. Also, consideration of safety and health principles is necessary in 3D printing and bioprinting workplaces.
Subject(s)
Bioprinting/methods , Neuromuscular Diseases/chemically induced , Occupational Exposure/adverse effects , Occupational Exposure/analysis , Printing, Three-Dimensional , Respiratory Tract Diseases/chemically induced , Air Pollutants/adverse effects , Air Pollutants/analysis , DNA Damage/drug effects , Humans , Inflammation Mediators/metabolism , Particulate Matter/adverse effects , Particulate Matter/analysis , Polymers/adverse effects , Polymers/analysisABSTRACT
Amiodarone is an antiarrhythmic medication with many side effects. Neuromyopathy is a rare adverse effect. We present an 87-year-old woman with bilateral leg pain and weakness in the context of amiodarone. She was admitted to the Acute Geriatric Unit in Calgary, Alberta, Canada. On examination, hip flexor and extensor strength were 2/5 bilaterally while knee flexor and extensor strength were 4/5 and 3/5, respectively. Creatine kinase and C-reactive protein levels were normal. MRI of the lumbar spine showed mild central canal stenosis. Electromyography and nerve conduction testing showed a severe axonal length-dependent polyneuropathy of the left lower extremity. There was evidence of myopathic changes to the left iliopsoas muscle. Overall, a neuromyopathic process affecting the lower extremities was supported. After discontinuation of amiodarone, mobility and function significantly improved. Although a rare complication of amiodarone, neuromyopathy should be considered in patients with compatible symptomatology.
Subject(s)
Amiodarone/adverse effects , Muscle, Skeletal/physiopathology , Neuromuscular Diseases/chemically induced , Aged, 80 and over , Anti-Arrhythmia Agents/adverse effects , Atrial Fibrillation/drug therapy , Electromyography , Female , Humans , Lower Extremity , Muscle, Skeletal/drug effects , Neuromuscular Diseases/diagnosis , Neuromuscular Diseases/physiopathology , Tomography, X-Ray ComputedABSTRACT
Immune checkpoint inhibitors (ICIs) are associated with various neurological adverse events (NAEs). We herein explored the incidence and clinical phenotype of immune-related NAEs in cancer patients. Medical records of ICI-treated cancer patients were reviewed between the years 2010 and 2018, with an aim to characterize immuno-related NAEs. A total of 1185 ICIs-treated patients were identified, 63.7% of which were males and 36.3% were females, with a mean age of 63.4 ± 7.3 years. Twenty-four from the overall ICIs-treated patients (2%) developed NAEs. No differences were identified in terms of age, sex, tumor type and class of ICIs between the patients who developed NAEs and those who did not. The median number of cycles of ICI treatment before NAEs onset were 4.5 (1-10), and the median time was 102 days. Peripheral nervous system (PNS) involvement was present in 14 patients (58.4%) and central nervous system (CNS) involvement in 10 (33.3%), including 2 patients with aseptic meningitis and polyradicular involvement. Amongst PNS complications, there were five (20.8%) with axonal sensory neuropathies, four (16.7%) with Guillain-Barre-like syndromes, and four (16.7%) with myositis and/or myasthenic syndromes. The majority of patients with PNS-related NAEs (n = 11; 78.6%) improved after ICIs discontinuation and treatment with immune-modulating therapies. The time to neuromuscular toxicities onset was significantly shorter, compared to CNS NAEs (median 70 vs 119 days, P = .037). Immune-related NAEs mostly present with neuromuscular complications. Discontinuation of ICIs and appropriate treatment should be commenced early throughout the process, in order to maximize a favorable outcome.
Subject(s)
Antineoplastic Agents, Immunological/toxicity , Central Nervous System Diseases/physiopathology , Drug-Related Side Effects and Adverse Reactions/physiopathology , Immune Checkpoint Inhibitors/toxicity , Neoplasms/drug therapy , Neuromuscular Diseases/physiopathology , Neurotoxicity Syndromes/physiopathology , Peripheral Nervous System Diseases/physiopathology , Aged , Antineoplastic Agents, Immunological/administration & dosage , Central Nervous System Diseases/chemically induced , Central Nervous System Diseases/drug therapy , Central Nervous System Diseases/epidemiology , Clinical Trials as Topic , Drug-Related Side Effects and Adverse Reactions/drug therapy , Drug-Related Side Effects and Adverse Reactions/epidemiology , Drug-Related Side Effects and Adverse Reactions/etiology , Female , Humans , Immune Checkpoint Inhibitors/administration & dosage , Immunologic Factors/pharmacology , Incidence , Male , Middle Aged , Neuromuscular Diseases/chemically induced , Neuromuscular Diseases/drug therapy , Neuromuscular Diseases/epidemiology , Neurotoxicity Syndromes/drug therapy , Neurotoxicity Syndromes/epidemiology , Neurotoxicity Syndromes/etiology , Peripheral Nervous System Diseases/chemically induced , Peripheral Nervous System Diseases/drug therapy , Peripheral Nervous System Diseases/epidemiologyABSTRACT
Immune checkpoint inhibitors (ICIs) are increasingly used and are becoming the standard of care in the treatment of various tumor types. Despite the favorable results in terms of oncological outcomes, these treatments have been associated with a variety of immune-related adverse events (irAEs). Neurological irAEs are rare but potentially severe. Neuromuscular disorders represent the most common neurological irAEs following anti-PD-1, anti-PD-L1, and anti-CTLA-4 treatment, and include myositis, myasthenia gravis, and demyelinating polyradiculoneuropathy. Instrumental findings may differ from typical neuromuscular disorders occurring outside ICIs treatment. Despite initial severity, neurological irAEs often respond to immune-modulating therapies. Prompt irAEs diagnosis, ICIs discontinuation, and early treatment with corticosteroids, together with patient education and a multi-disciplinary approach, are important for optimizing clinical outcomes. Intravenous immunoglobulin, plasma exchange, and other immune-modulating treatments should be considered in more severe cases. Consideration of re-challenging with the same immunotherapy drug may be given in some cases, based on clinical picture and initial severity of irAEs.
Subject(s)
Antineoplastic Agents, Immunological/adverse effects , Immunotherapy/adverse effects , Neuromuscular Diseases/chemically induced , Neuromuscular Diseases/immunology , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents, Immunological/immunology , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/adverse effects , Immunologic Factors/immunology , Neuromuscular Diseases/therapy , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Programmed Cell Death 1 Receptor/immunology , Treatment OutcomeABSTRACT
OBJECTIVES: The objective of this study was to assess risk of neurological toxicities following the use of different immune checkpoint inhibitor (ICI) regimens in solid tumors. METHODS: Pubmed, Embase, and ClinicalTrials.gov databases were searched for publications, and data were analyzed using Review Manager 5.3 software to compare the risk of immune-related and nonspecific neurological complications potentially triggered by ICIs to controls. RESULTS: In total 23 randomized clinical trials comprising 11,687 patients were included in this meta-analysis. Patients with PD-L1 (OR, 0.29; 95% confidence interval [CI], 0.18-0.48; P<0.01) or programmed cell-death protein 1 (PD-1) inhibitor (OR, 0.21; 95% CI, 0.14-0.31; P<0.01) were less likely to develop any-grade peripheral neuropathy than chemotherapy, while the risk of grade 3-5 was also smaller for PD-1 inhibitor (OR, 0.16; 95% CI, 0.05-0.54; P=0.003). Combination therapy with CTLA4 and PD-1 inhibitor did not significantly increase the risk of any-grade (OR, 0.83; 95% CI, 0.21-3.32; P>0.05) or grade 3-5 (OR, 1.4; 95% CI, 0.2-9.61; P>0.05) peripheral neuropathy compared to monotherapy with CTLA4 or PD-1 inhibitor. However, difference in risk of immune-related adverse events (irAEs) involving central nervous system did not reach statistical significance in patients with different ICI regimens compared those under chemotherapy. Additionally, risk of experiencing paresthesia was in line with that of peripheral neuropathy (OR, 0.42; 95% CI, 0.28-0.62; P<0.01). CONCLUSIONS: This meta-analysis shows that PD-L1/PD-1 and CTLA4 inhibitor have decreased risk of peripheral neuropathy compared to chemotherapy, while combination therapy with CTLA4 and PD-1 inhibitor have no difference in neurological toxicities compared to monotherapy with CTLA4 or PD-1 inhibitor.
Subject(s)
Antineoplastic Agents, Immunological/adverse effects , Neoplasms/drug therapy , Neurotoxicity Syndromes/epidemiology , B7-H1 Antigen/antagonists & inhibitors , CTLA-4 Antigen/antagonists & inhibitors , Guillain-Barre Syndrome/chemically induced , Humans , Myasthenia Gravis/chemically induced , Myositis/chemically induced , Neuromuscular Diseases/chemically induced , Peripheral Nervous System Diseases/chemically induced , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Randomized Controlled Trials as Topic , Risk FactorsABSTRACT
INTRODUCTION: Checkpoint inhibitors have dramatically transformed cancer treatment. However, due to the increasing number of tumors in which they are used, there is a high number of reported adverse effects. Among them, we highlight neurological side effects. In the approbatory clinical trials, they were thought to be sparse, but they may have been underestimated. AIM: To review the physiopathology and the incidence of neurological side effects due to the use of checkpoint inhibitors, as well as the clinical practice guidelines published in the last years. DEVELOPMENT: To review the published case reports of neurological side effects since the approval of checkpoint inhibitors, and our own experience. Moreover, we summarize the main clinical practice guidelines. CONCLUSIONS: Checkpoint inhibitors neurological side effects are frequent. A wide variety of central or peripheral nervous system symptoms may develop. In the setting of brain tumors, inflammation due to immune system activation might lead to pseudoprogression. Further studies are needed to better describe these neurological side effects, and to implement clinical guidelines.
TITLE: Complicaciones neurologicas de los inhibidores de punto de control inmunologico.Introduccion. Los inhibidores de punto de control inmunologico han supuesto un nuevo paradigma en el tratamiento de diferentes tipos de neoplasias. Sin embargo, con el uso creciente de estos farmacos, se estan observando diferentes efectos adversos. Entre ellos destacan los neurologicos, puesto que su frecuencia parece haberse infraestimado en los ensayos aprobatorios. Objetivo. Revisar la fisiopatologia y la incidencia de los efectos adversos neurologicos por inhibidores de punto de control neurologicos, asi como el abordaje basandose en diferentes guias clinicas. Desarrollo. Se revisan los casos que se han publicado desde la aprobacion de los farmacos y añadimos la experiencia de nuestro centro. A su vez, se hace un resumen de las diferentes guias publicadas de forma reciente. Conclusiones. Las complicaciones derivadas del uso de los inhibidores de punto de control inmunologico son frecuentes. Incluyen multiples cuadros de diferente gravedad, y pueden afectar a cualquier parte del sistema nervioso central y periferico. Ademas, en tumores del sistema nervioso, puede observarse un fenomeno de pseudoprogresion derivado de la inflamacion asociada. Queda pendiente realizar nuevos estudios para conocer en detalle estos efectos adversos y desarrollar guias clinicas con las que optimizar el manejo.
Subject(s)
Antineoplastic Agents/adverse effects , B7-H1 Antigen/antagonists & inhibitors , CTLA-4 Antigen/antagonists & inhibitors , Immunotherapy , Molecular Targeted Therapy , Neoplasm Proteins/antagonists & inhibitors , Neoplasms/drug therapy , Nervous System Diseases/chemically induced , Neuromuscular Diseases/chemically induced , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Animals , Antineoplastic Agents/pharmacology , B7-H1 Antigen/physiology , Brain Neoplasms/drug therapy , Brain Neoplasms/immunology , CTLA-4 Antigen/deficiency , CTLA-4 Antigen/physiology , Clinical Trials as Topic , Humans , Immunotherapy/adverse effects , Mice , Mice, Knockout , Molecular Targeted Therapy/adverse effects , Neoplasm Proteins/physiology , Neoplasms/immunology , Nervous System Diseases/therapy , Neuromuscular Diseases/therapy , Practice Guidelines as Topic , Programmed Cell Death 1 Receptor/physiologyABSTRACT
Neuromuscular adverse events following cancer treatment with anti-programmed cell death protein 1 (PD-1) monoclonal antibodies are relatively rare, yet potentially fatal. We performed a systematic review to characterize the clinical presentation, diagnostic workup, and management of neuromuscular disorders (NMDs) in patients treated with nivolumab or pembrolizumab monotherapy or concurrent with other immunologic agents, such as ipilimumab. Sixty-one publications on 85 patients (mean age 66.9 years [range 34-86]; male/female 2.6:1; 59% metastatic melanoma) were identified from selected indexing databases until June 2018. Forty-eight patients had received nivolumab and 39 pembrolizumab. The mean number of PD-1 inhibitor treatment cycles prior to onset of symptoms was 3.6 (range 1-28). Symptoms included oculomotor (47%), respiratory (43%), bulbar (35%), and proximal weakness (35%), as well as muscle pain (28%). Diagnoses were categorized as myasthenia gravis (27%), neuropathy (23%), myopathy (34%), or a combination of these (16%). After a critical review of the data, however, evidence did not support the stated NMD diagnosis in 13% of cases, while up to 25% of patients had signs of additional NMDs. Cardiac complications occurred in more than 30% of patients diagnosed with myasthenia gravis or myositis. Mortality was high in these patients, despite adequate treatment strategies including corticosteroid, IV immunoglobulins, and plasma exchange. The clinical presentation of NMDs associated with PD-1 inhibitors is often atypical, with considerable overlap between myasthenia gravis and myopathy, and cardiac/respiratory complications are common.
Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Antineoplastic Agents, Immunological/adverse effects , Neuromuscular Diseases/chemically induced , Nivolumab/adverse effects , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Adrenal Cortex Hormones/therapeutic use , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Muscular Diseases/chemically induced , Muscular Diseases/therapy , Myasthenia Gravis/chemically induced , Myasthenia Gravis/therapy , Myositis/chemically induced , Myositis/therapy , Neuromuscular Diseases/therapy , Peripheral Nervous System Diseases/chemically induced , Peripheral Nervous System Diseases/therapy , Plasma ExchangeABSTRACT
AIM: To characterise clinical presentation, laboratory and histopathologic characteristics and assess the treatment and outcome of neuromuscular side-effects of checkpoint therapy. METHODS: The side-effect registry and the institutional database from ten skin cancer centres were queried for reports on myositis and neuromuscular side-effects induced by checkpoint inhibitors. In total, 38 patients treated with ipilimumab, tremelimumab, nivolumab and pembrolizumab for metastatic skin cancer were evaluated and characterised. RESULTS: Myositis was the most frequent neuromuscular adverse event. In 32% of cases, myositis was complicated by concomitant myocarditis. Furthermore, cases of isolated myocarditis, myasthenia gravis, polymyalgia rheumatica, radiculoneuropathy and asymptomatic creatine kinase elevation were reported. The onset of side-effects ranged from the first week of treatment to 115 weeks after the start of therapy. Most of the cases were severe (49% grade III-IV Common Terminology Criteria for Adverse Events), and there were two fatalities (5%) due to myositis and myositis with concomitant myocarditis. Only half of the cases (50%) completely resolved, whereas the rest was either ongoing or had sequelae. Steroids were given in 80% of the resolved cases and in 40% of the unresolved cases. CONCLUSION: Immune-mediated neuromuscular side-effects of checkpoint inhibitors greatly vary in presentation and differ from their idiopathic counterparts. These side-effects can be life threatening and may result in permanent sequelae. Occurrence of these side-effects must be taken into consideration for patient information, especially when considering adjuvant immunotherapy with anti-programmed cell-death protein 1 (PD-1) antibodies and monitoring, which should include regular surveillance of creatine kinase.
Subject(s)
Antineoplastic Agents, Immunological/adverse effects , Myositis/chemically induced , Neuromuscular Diseases/chemically induced , Skin Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Databases, Factual , Female , Germany , Humans , Male , Middle Aged , Molecular Targeted Therapy/adverse effects , Myositis/diagnosis , Myositis/immunology , Myositis/therapy , Neoplasm Metastasis , Neuromuscular Diseases/diagnosis , Neuromuscular Diseases/immunology , Neuromuscular Diseases/therapy , Registries , Retrospective Studies , Risk Assessment , Risk Factors , Skin Neoplasms/immunology , Skin Neoplasms/pathology , Switzerland , Time Factors , Young AdultABSTRACT
Immune checkpoint inhibitors have been increasingly used in patients with various cancers. Despite favourable oncological outcomes these treatments have also been associated with immune-related adverse events. Neurological irAE are rare but potentially severe and neuromuscular complications are the most common. This is a new group of neurologic complications of systemic anticancer therapies, often responsive to immune-modulating therapies. Early recognition and treatment are crucial for timely improvement of functional outcome and requires a multidisciplinary approach.
Subject(s)
Immunotherapy/adverse effects , Neoplasms/drug therapy , Neuromuscular Diseases/chemically induced , Protein Kinase Inhibitors/adverse effects , Cell Cycle Checkpoints/immunology , Humans , Immunotherapy/methods , Myasthenia Gravis/chemically induced , Myasthenia Gravis/diagnosis , Myasthenia Gravis/therapy , Myositis/chemically induced , Myositis/diagnosis , Myositis/therapy , Neuromuscular Diseases/diagnosis , Neuromuscular Diseases/epidemiology , Neuromuscular Diseases/therapy , Peripheral Nervous System Diseases/chemically induced , Peripheral Nervous System Diseases/diagnosis , Peripheral Nervous System Diseases/therapy , Protein Kinase Inhibitors/therapeutic useABSTRACT
Immunomodulating drugs are widely used in autoimmune, transplant, and cancer patients. However, these drugs are associated with various autoimmune neuromuscular diseases such as demyelinating polyneuropathy, myasthenia gravis, and myositis. Early recognition of these complications and immediately terminating these drugs are very essential since some are life-threatening conditions. This review provides a general overview of drug-induced autoimmunity and autoimmune neuromuscular diseases associated with tumor necrosis factor alpha (TNF-α) antagonists, immune checkpoint inhibitors, and interferon (IFN) type 1 (IFN-ß and IFN-α).
Subject(s)
Autoimmune Diseases/chemically induced , Immunologic Factors/adverse effects , Neuromuscular Diseases/chemically induced , Animals , Autoantibodies/immunology , Autoimmune Diseases/complications , Humans , Neuromuscular Diseases/complicationsABSTRACT
Neuromuscular adverse events(AEs)associated with cancer treatment with immune checkpoint inhibitors(ICIs)include diverse clinical subsets. The general features of neuromuscular AEs have not been elucidated because the frequency is generally low, ranging from 1-2%of cancer patients undergoing ICIs therapy. The diseases affect the central nervous system, peripheral nerves, neuromuscular junction, and muscle. Disease onset and progression may be rapid with a critical clinical course. The clinical presentation may be different from that of patients unrelated to drugs. Headache, dizziness, and dysgeusia were relatively common and mild treatment-related AEs. In contrast, representative immune-related AEs such as autoimmune encephalitis, demyelinating polyneuropathy, myasthenia, and myositis were serious. There was a tight association between myasthenia, myositis, and myocarditis. There are guidelines for the treatment of neuromuscular immune-mediated AEs. For all but the minimum neurological symptoms, checkpoint inhibitor therapy should be withheld until the nature of the AEs is defined. Immune-modulating medication is generally effective for neuromuscular AEs. Both CD8+ cytotoxic T-cells and autoantibodies are involved in the pathogenesis of neuromuscular AEs. Correct understanding of neuromuscular AEs is required for the best management of cancer patients.
Subject(s)
Molecular Targeted Therapy/adverse effects , Neoplasms/drug therapy , Neuromuscular Diseases/chemically induced , Humans , Neoplasms/immunology , Neuromuscular Diseases/therapy , PrognosisSubject(s)
Antineoplastic Agents/adverse effects , Benzimidazoles/adverse effects , MAP Kinase Kinase Kinases/antagonists & inhibitors , Melanoma/drug therapy , Neck Muscles/drug effects , Neuromuscular Diseases/chemically induced , Protein Kinase Inhibitors/adverse effects , Skin Neoplasms/drug therapy , Antineoplastic Agents/administration & dosage , Benzimidazoles/administration & dosage , Chemotherapy, Adjuvant , GTP Phosphohydrolases/genetics , Humans , MAP Kinase Kinase Kinases/metabolism , Male , Melanoma/enzymology , Melanoma/genetics , Melanoma/secondary , Membrane Proteins/genetics , Middle Aged , Mutation , Neck Muscles/diagnostic imaging , Neck Muscles/physiopathology , Neuromuscular Diseases/diagnosis , Neuromuscular Diseases/physiopathology , Protein Kinase Inhibitors/administration & dosage , Skin Neoplasms/enzymology , Skin Neoplasms/genetics , Skin Neoplasms/pathology , Syndrome , Treatment OutcomeABSTRACT
The neuromuscular junction activity of Oxyuranus scutellatus venom and its presynaptic neurotoxin, taipoxin, and their neutralization by two antivenoms were examined in mouse phrenic nerve-diaphragm preparations. The action of taipoxin was also studied at 21°C. The efficacy of the antivenoms was also assessed in an in vivo mouse model. Both antivenoms were effective in neutralizing the neuromuscular blocking activity in preincubation-type experiments. In experiments involving independent addition of venom and antivenoms, neutralization depended on the time interval between venom addition and antivenom application. When taipoxin was incubated for 5, 10 or 20min at 21°C, and antivenom added and temperature increased to 37°C, neutralization was achieved only when the toxin was incubated for 5 or 10min. The neutralization by the two antivenoms in an in vivo model showed that both whole IgG and F(ab')2 antivenoms were effective in neutralizing lethality. Our findings highlight the very rapid action of taipan venom at the nerve terminal, and the poor capacity of antivenoms to revert neurotoxicity as the time interval between venom or taipoxin application and antivenom addition increased. Additionally the disparity between molecular masses of the active substances of the two antivenoms did not result in differences in neutralization.
Subject(s)
Antivenins/pharmacology , Elapid Venoms/antagonists & inhibitors , Elapid Venoms/toxicity , Elapidae , Immunoglobulin Fab Fragments/pharmacology , Immunoglobulin G/pharmacology , Neuromuscular Diseases/chemically induced , Neuromuscular Diseases/prevention & control , Neuromuscular Junction/drug effects , Neurotoxins/antagonists & inhibitors , Neurotoxins/toxicity , Animals , Diaphragm/drug effects , In Vitro Techniques , Lethal Dose 50 , Male , Mice , Muscle Contraction/drug effects , Phrenic Nerve/drug effects , TemperatureABSTRACT
Venoms of snakes and scorpions pose a significant threat to the health and life of humans. The speed and range of their actions causes damage of the organ responsible for the maintenance of vital signs. Venomous snake venoms cause blood clotting disorders, tissue necrosis and hemolysis, and the release of a number of proinflammatory cytokines and impair antibody synthesis. Availability of antitoxins is limited and in the most cases supportive treatment is recommended. In turn, the venom of scorpions beside intestinal symptoms cause significant impairment of neuromuscular conduction, causing severe respiratory disorders. Action venom poses a particular threat to sensitive patients. The degree of threat to life caused by the venom of snakes and scorpions authorizes the treatment of these substances as a potential biological weapon.